295 related articles for article (PubMed ID: 34661144)
1. Hedgehog Pathway Inhibitors: A New Therapeutic Class for the Treatment of Acute Myeloid Leukemia.
Jamieson C; Martinelli G; Papayannidis C; Cortes JE
Blood Cancer Discov; 2020 Sep; 1(2):134-145. PubMed ID: 34661144
[TBL] [Abstract][Full Text] [Related]
2. Targeting Hedgehog (Hh) Pathway for the Acute Myeloid Leukemia Treatment.
Terao T; Minami Y
Cells; 2019 Apr; 8(4):. PubMed ID: 30987263
[TBL] [Abstract][Full Text] [Related]
3. Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia.
Shallis RM; Bewersdorf JP; Boddu PC; Zeidan AM
Expert Rev Anticancer Ther; 2019 Aug; 19(8):717-729. PubMed ID: 31422721
[No Abstract] [Full Text] [Related]
4. [Efficacy of Hedgehog inhibitors in acute myeloid leukemia and establishment of valid biomarkers].
Minami Y
Rinsho Ketsueki; 2019; 60(7):843-846. PubMed ID: 31391375
[TBL] [Abstract][Full Text] [Related]
5. NANOG Expression as a Responsive Biomarker during Treatment with Hedgehog Signal Inhibitor in Acute Myeloid Leukemia.
Kakiuchi S; Minami Y; Miyata Y; Mizutani Y; Goto H; Kawamoto S; Yakushijin K; Kurata K; Matsuoka H; Minami H
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28245563
[TBL] [Abstract][Full Text] [Related]
6. Nonhematopoietic cells represent a more rational target of in vivo hedgehog signaling affecting normal or acute myeloid leukemia progenitors.
Boyd AL; Salci KR; Shapovalova Z; McIntyre BA; Bhatia M
Exp Hematol; 2013 Oct; 41(10):858-869.e4. PubMed ID: 23747997
[TBL] [Abstract][Full Text] [Related]
7. The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia.
Wu A; Turner KA; Woolfson A; Jiang X
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986819
[TBL] [Abstract][Full Text] [Related]
8. Hedgehog/GLI signaling in hematopoietic development and acute myeloid leukemia-From bench to bedside.
Tesanovic S; Krenn PW; Aberger F
Front Cell Dev Biol; 2022; 10():944760. PubMed ID: 35990601
[TBL] [Abstract][Full Text] [Related]
9. GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.
Chaudhry P; Singh M; Triche TJ; Guzman M; Merchant AA
Blood; 2017 Jun; 129(26):3465-3475. PubMed ID: 28487292
[TBL] [Abstract][Full Text] [Related]
10. Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.
Aberger F; Hutterer E; Sternberg C; Del Burgo PJ; Hartmann TN
Cell Commun Signal; 2017 Jan; 15(1):8. PubMed ID: 28122581
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells.
Kobune M; Takimoto R; Murase K; Iyama S; Sato T; Kikuchi S; Kawano Y; Miyanishi K; Sato Y; Niitsu Y; Kato J
Cancer Sci; 2009 May; 100(5):948-55. PubMed ID: 19245435
[TBL] [Abstract][Full Text] [Related]
12. The BET bromodomain inhibitor ZEN-3365 targets the Hedgehog signaling pathway in acute myeloid leukemia.
Wellbrock J; Behrmann L; Muschhammer J; Modemann F; Khoury K; Brauneck F; Bokemeyer C; Campeau E; Fiedler W
Ann Hematol; 2021 Dec; 100(12):2933-2941. PubMed ID: 34333666
[TBL] [Abstract][Full Text] [Related]
13. Hedgehog Signaling in Myeloid Malignancies.
Abraham A; Matsui W
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638372
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog pathway activation in chronic myeloid leukemia.
Jagani Z; Dorsch M; Warmuth M
Cell Cycle; 2010 Sep; 9(17):3449-56. PubMed ID: 20928937
[TBL] [Abstract][Full Text] [Related]
15. Deregulated hedgehog pathway signaling is inhibited by the smoothened antagonist LDE225 (Sonidegib) in chronic phase chronic myeloid leukaemia.
Irvine DA; Zhang B; Kinstrie R; Tarafdar A; Morrison H; Campbell VL; Moka HA; Ho Y; Nixon C; Manley PW; Wheadon H; Goodlad JR; Holyoake TL; Bhatia R; Copland M
Sci Rep; 2016 May; 6():25476. PubMed ID: 27157927
[TBL] [Abstract][Full Text] [Related]
16. HDAC6 inhibition decreases leukemic stem cell expansion driven by Hedgehog hyperactivation by restoring primary ciliogenesis.
Pezzotta A; Gentile I; Genovese D; Totaro MG; Battaglia C; Leung AY; Fumagalli M; Parma M; Cazzaniga G; Fazio G; Alcalay M; Marozzi A; Pistocchi A
Pharmacol Res; 2022 Sep; 183():106378. PubMed ID: 35918044
[TBL] [Abstract][Full Text] [Related]
17. Hedgehog pathway as a drug target: Smoothened inhibitors in development.
Lin TL; Matsui W
Onco Targets Ther; 2012; 5():47-58. PubMed ID: 22500124
[TBL] [Abstract][Full Text] [Related]
18. Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Fimognari F; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(14):1537-1543. PubMed ID: 37392098
[TBL] [Abstract][Full Text] [Related]
19. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells.
Fukushima N; Minami Y; Kakiuchi S; Kuwatsuka Y; Hayakawa F; Jamieson C; Kiyoi H; Naoe T
Cancer Sci; 2016 Oct; 107(10):1422-1429. PubMed ID: 27461445
[TBL] [Abstract][Full Text] [Related]
20. Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status.
Cea M; Cagnetta A; Cirmena G; Garuti A; Rocco I; Palermo C; Pierri I; Reverberi D; Nencioni A; Ballestrero A; Gobbi M; Carella AM; Patrone F
Leuk Lymphoma; 2013 Feb; 54(2):342-52. PubMed ID: 22762548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
